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Abstract. – OBJECTIVE: Samter’s triad is the 
combination of asthma, aspirin sensitization, 
and nasal polyposis. Few data are available on 
the use of omalizumab in this disease. The study 
aimed to describe the impact of omalizumab on 
clinical and functional parameters and the quali-
ty of life of a series of patients with Samter’s tri-
ad. Moreover, we aimed to provide a review of 
the literature on this topic.
PATIENTS AND METHODS: We retrospective-
ly described four patients with Samter’s triad 
undergoing omalizumab therapy. Clinical, func-
tional, and immunological data of these patients 
were collected at baseline and follow-up.
RESULTS: Reduction of asthma exacerbations 
and salbutamol rescue therapy were observed 
in all patients after anti-IgE treatment together 
with an improvement in the quality of life. A sig-
nificant improvement in FEV1, FVC, and FEF25-
75 was observed. No major side-effects were 
observed. A total of 14 studies regarding omal-
izumab in aspirin-exacerbated respiratory dis-
eases were included in the review, comprising 
78 patients. All studies reported a good efficacy 
in improving asthma control; restoration of aspi-
rin tolerance was repeatedly reported.
CONCLUSIONS: The results of our case se-
ries and review of the literature suggest that 
omalizumab effectively improves asthma con-
trol, lung function tests, and quality of life in pa-
tients with Samter’s triad.
Key Words:
Omalizumab, Samter’s triad, Therapy, Anti-IgE. 
Introduction
The combination of asthma, nasal polyposis, 
and sensitization to aspirin is currently known 
as Samter’s triad1. It was first described in 1922 
by Widal et al2 and is an aspirin-exacerbated 
respiratory disease (AERD), affecting 15% of 
all patients with severe asthma3. From the patho-
genetic point of view, AERD is characterized 
by massive infiltration of mastocytes, basophils, 
and eosinophils of the rhinosinus and respiratory 
mucosa, determining an over-production of leu-
kotrienes and prostaglandins (in particular, LTE4 
and PGD2)4, whose action is further enhanced 
by the upregulation of specific receptors5. From 
the clinical point of view, the onset of asthma in 
the AERD generally occurs in the third-fourth 
decade of life with persistent, difficult-to-control 
asthma and a predisposition for early bronchial 
remodelling6. The standard medical treatment is 
based on inhaled and/or systemic steroids, com-
bined with anti-leukotrienes, inhaled broncho-
dilators, and aspirin desensitization protocols7,8. 
This approach may not be sufficient, and patients 
may present unsatisfactory quality of life with 
major drug-induced side effects. Biological thera-
pies approved for severe asthma could, therefore, 
be interesting in this context.
Omalizumab is a recombinant anti-IgE hu-
manised monoclonal antibody9. Its efficacy in 
improving symptoms and reducing exacerbation 
rate in patients with severe asthma, resulting in 
a significant “steroid-sparing” effect, has been 
repeatedly demonstrated10,11. However, no clinical 
trials have yet been conducted in this specific 
setting. Here we describe a case series of four 
patients with Samter’s triad, treated with omali-
zumab to evaluate its clinical effect, followed by 
a review of the literature concerning this topic.
Patients and Methods
We retrospectively collected four patients (3 
males, 53 ± 14 years old) with Samter’s triad, 
who were followed at our Centre. Clinical, demo-
graphic, functional, hematochemical, and immu-
nological data were collected prior to initiation of 
omalizumab therapy and at follow-up (13 ± 5.1 
months). The clinical control of asthma and nasal 
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polyposis was assessed by the Asthma Control 
Test (ACT) and Sino Nasal Outcome Test-22 
(SNOT22) questionnaires. The study design was 
approved by the Ethics Committee of Siena Uni-
versity (Italy).
Clinical, functional, serological, and demo-
graphic features are reported in Table I. Patient 
1, 2, and 4 started omalizumab therapy due to 
severe asthma associated with atopic sensibili-
zation to perennial allergens. Patient 3 was on 
therapy with omalizumab at the dose approved 
for Spontaneous Chronic Urticaria (CSU)12, as 
he showed no sensitization to perennial allergens 
and no flow limitation at pulmonary function tests 
(PFTs). No patient had ever performed aspirin de-
sensitization or specific allergen immunotherapy 
due to severe asthmatic symptoms. At baseline, 
all patients were on treatment with a high dose 
of inhaled corticosteroids (ICS) associated with 
inhaled long-acting β-2 agonists (LABA) and 
montelukast; all except for patient 3 were also 
in treatment with long-acting muscarinic recep-
tors antagonists (LAMA) (tiotropium). Patient 4 
was also treated with daily oral steroids (OCS) 
to maintain an acceptable control of asthma and 
nasal disease, while the other patients performed 
recurrent cycles of OCS. Concerning function-
al parameters, all patients (except for patient 
3) showed mild-to-moderate obstructive impair-
ment. All patients reported at least two moderate 
or severe asthmatic exacerbations requiring high 
doses of OCS and antibiotics in the previous year 
of omalizumab therapy. Regarding nasal polyp-
osis, patient 1, 2, and 3 underwent functional 
endoscopic sinus surgery (FESS) twice, once and 
twice, respectively. Patients 1, 2, and 4 were on 
chronic therapy with combined intranasal ste-
roids and azelastine, while patient 3 was taking 
only nasal steroid spray.
At follow-up (13 ± 5.1 months, media ± SD), 
there was a notable clinical improvement of asth-
ma and nasal polyposis control, certified by ACT 
and SNOT22 scores’ improvement and by a sig-
nificantly reduced use of rescue bronchodilator 
therapies. Of the three patients on treatment 
with as-needed salbutamol, two did not resort to 
rescue therapy at all; and patient 4 reduced sal-
butamol from an average of 5 to 2 weekly doses. 
Concerning exacerbations of asthma, only patient 
4 reported a single mild episode associated with 
an acute viral rhinitis. All patients with FEV1 < 
80% of predicted at baseline, showed a significant 
improvement at follow-up, with normalization of 
lung parameters  in 2/3 cases. Regarding mainte-
nance therapy, no patient was taking OCS, and 
patient 4 reduced daily ICS dose (from 750 to 400 
µg/day, beclometasone equivalent). Surgical nasal 
polypectomy or FESS was not necessary during 
omalizumab therapy. No considerable modifica-
tions of intranasal treatment were made during 
the observation period. Eosinophilic blood counts 
showed a clear reduction in all patients. Omali-
zumab was very well tolerated, and no medium 
or severe side effects were observed: in the first 
2 months of omalizumab therapy, a single patient 
reported frontal headache that subsequently re-
solved spontaneously.
Discussion and Review of the Literature
Omalizumab is a recombinant monoclonal an-
tibody (mAb) that binds the Fcε portion of the 
immunoglobulin (Ig)E antibodies. It reduces the 
total IgE levels preventing interaction with the 
high-affinity receptors (FcεRI) expressed on the 
surface of the target cells, receptor expression and 
the resulting inflammatory cascade13,14. Omali-
zumab has been licensed since 2003 by the Food 
and Drug Administration (FDA) and since 2005 
by European Medicines Agency (EMA) for the 
treatment of moderate-to-severe allergic asthma 
in adults and adolescents (≥ 12 years) with sensi-
tization to a perennial allergen and symptoms not 
controlled by inhaled corticosteroids (ICS). 
The clinical efficacy and safety of omalizumab 
in severe asthma have already been extensively 
demonstrated in many studies11,12,15. Several clini-
cal trials have also investigated the utility of omal-
izumab for the treatment of different IgE-related 
diseases besides allergic asthma, such as allergic 
rhinitis, food and drugs allergy, allergic broncho-
pulmonary aspergillosis, atopic dermatitis, eosin-
ophilic granulomatosis with polyangiitis (EGPA) 
or mastocytosis16-22, with promising results.  In 
our case series, omalizumab proved to be a safe 
and effective treatment in a specific syndrome 
such as Samter’s triad. The reduction in asthma 
exacerbation and decreased use of OCS revealed 
a significant improvement in disease control and 
quality of life, as certified by an increase in ACT 
score. Moreover, SNOT-22 declined significantly, 
along with peripheral eosinophilic count. These 
results confirm the systemic overall effectiveness 
of omalizumab in reducing the burden of eo-
sinophilic and inflammatory activity, as already 
reported in the literature23,24. Our data25 confirms 
the effectiveness of omalizumab in improving 
sino-nasal clinical and radiological outcomes in 
these patients, as previously demonstrated, even 
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compared with the surgical approach26. With this 
case series, we supported the potential utility of 
omalizumab in the management of AERDs: how-
ever, in our patients, its efficacy may be explained 
by the fact that 3/4 patients were sensitized to 
perennial allergens.
In literature, there are limited studies on this 
topic. The only specific available evidence of 
omalizumab use in Samter’s triad comes from 
two case reports27,28 and a single case series of 
3 patients29. All these studies reported a good 
efficacy of omalizumab in improving asthma 
control. Moreover, in the case series, omalizum-
ab significantly decreased eosinophilic cationic 
peptide, exhaled nitric oxide, interleukin-1β, and 
C-reactive protein levels, although these results 
were not associated with a significant improve-
ment of nasal polyposis. 
Other small-sized observational studies or case 
series investigated the utility of omalizumab in 
the clinical management of patients with AERDs, 
therefore including also Samter’s triad cases. Tio-
tiu et al30 recently described a cohort of 21 patients 
with severe asthma and nasal polyps, including 9 
subjects with aspirin intolerance. The results are 
in line with our data, showing a good clinical and 
radiological response associated to a decrease 
of peripheral eosinophilic cell count. The same 
findings were reported in a multi-center random-
ized placebo-controlled trial of omalizumab in 
patients with asthma and nasal polyposis, even 
though the outcomes related to AERDs were 
not specifically assessed31. Hayashi et al32 con-
firmed the reliability of omalizumab in a small 
cohort of patients with AERDs. Interestingly, the 
authors also reported a significant reduction in 
the urinary concentrations of LTE4 and PGD2, 
suggesting a specific activity of omalizumab in 
modulating this subtype of inflammation.
Concerning aspirin hypersensitivity, three case 
reports have first described the effectiveness of 
omalizumab in restoring the tolerance to aspi-
rin28,33,34. These promising results were subse-
quently detected in a case series by Phillips-An-
gles et al35 in which FANS tolerance was restored 
in 4 out of 6 patients. The underlying mecha-
nisms for which omalizumab may be specifically 
effective in AERDs are not clear. Omalizumab 
is able not only to bind and inactivate serum 
free IgE, but also to detach IgE from FcεRI in 
basophils, dendritic cells, and mast cells36. The 
consequent surface IgE downregulation may de-
termine a decrease production of LTs and other 
mediators by mast cells and basophils, that are 
crucial in the pathogenesis of AERDs. A specif-
ic activity in restoring aspirin tolerance per se 
by omalizumab is further supported by a case 
report of a non-asthmatic woman affected with 
chronic spontaneous urticaria37. Our results are 
in line with these previous results, supporting the 
beneficial effect of omalizumab in reducing mast 
cell and eosinophilic inflammatory burden and 
aspirin-induced respiratory diseases. 
Finally, some authors investigated the poten-
tial use of omalizumab to prevent adverse events 
during aspirin desensitization, reporting conflict-
ing results. The first case report by Guillén et 
al38 showed positive results, while a retrospective 
single-center study by Waldram et al39, including 
9 patients treated with omalizumab, did not show 
any difference in terms of safety. However, in a 
randomized controlled trial recently published by 
Lang et al40, omalizumab use was associated with 
a significant reduction of adverse events during 
desensitization, suggesting a potential implemen-
tation of the drug on this setting.
Conclusions
Despite the limited data available in the ex-
isting literature, omalizumab has proved to be 
effective and safe for the use in patients with 
Samter’s triad. The evidence that omalizumab 
decreases mast cell and basophils activity, induc-
ing a reduction of LTE4 production, suggests that 
its activity goes beyond the inhibition of the free 
serum IgE. Therefore, the use of omalizumab in 
patients with Samter’s triad, and, in general, with 
AERDs, may be proposed as a valid therapeutic 
option. A randomized clinical trial to confirm 
these previous results is strongly needed.
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